Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider?

Title Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider?
Journal Expert Review of Cardiovascular Therapy
Authors Ergui I, Lamas GA
Year Published 2016
Link to article

Expert commentary
Chelation reduced adverse cardiovascular events in a post myocardial infarction (MI) population. Patients with diabetes demonstrated even greater benefit, with a number needed to treat of 6.5 patients to prevent a cardiac event over 5 years, with a 41% relative reduction in risk of a cardiac event (p = 0.0002). These results led to the revision of the ACC/AHA guideline recommendations for chelation therapy, changing its classification from class III to class IIb. TACT2, a replicative trial, will assess the effects of chelation therapy on cardiovascular outcomes in diabetic patients with a prior myocardial infarction. We are seeking participating sites for TACT2.

Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients

Title Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients
Journal Trends in Cardiovascular Medicine
Authors Peguero JG, Arenas I, Lamas GA.
Year Published 2014
Link to article
Link to abstract

Conclusions
Among patients with a prior MI, a regimen of 40 infusions of disodium EDTA-based infusions safely reduced cardiovascular events in a post-MI population, suggesting that xenobiotic metal pollutants are cardiovascular risk factors. The effect of the chelation infusions was enhanced with high doses of oral multivitamins and multiminerals. The therapeutic benefit was particularly striking in diabetic patients. These results were observed against a background of modern evidence-based post-MI therapy.

Chelation Therapy Reduces Cardiovascular Events for Older Patients with Diabetes

Chelation treatments reduce cardiovascular events, such as heart attacks, and death in patients with diabetes but not in those who did not have diabetes, according to analyses of data from the National Institutes of Health-funded Trial to Assess Chelation Therapy (TACT). However, researchers say more research is needed before it’s known whether this promising finding leads to a treatment option.

Read more

The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT)

Title Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction
Journal Circ Cardiovasc Qual Outcomes
Authors Escolar E, Lamas GA, Mark DB, Boineau R, Goertz C, Rosenberg Y, Nahin RL, Ouyang P, Rozema T, Magaziner A, Nahas R, Lewis EF, Lindblad L, Lee KL
Year Published 2014
Link to article
Link to abstract

Conclusions:
Post-myocardial infarction patients with diabetes mellitus aged ≥50 demonstrated a marked reduction in cardiovascular events with EDTA chelation. These findings support efforts to replicate these findings and define the mechanisms of benefit. However, they do not constitute sufficient evidence to indicate the routine use of chelation therapy for all post-myocardial infarction patients with diabetes mellitus.